-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$127.159.33% Upside
Horizon Therapeutics Public Limited Company Frequently Asked Questions
-
What analysts cover Horizon Therapeutics Public Limited Company?
Horizon Therapeutics Public Limited Company has been rated by research analysts at Guggenheim, Leerink Partners, Wells Fargo, Piper Sandler, Stifel Nicolaus, UBS in the past 90 days.